Abstract
Cancer genomes acquire somatic alterations that largely differ between and within cancer types. Several of these alterations inactivate genes that are normally functional with no deleterious consequences on cancer cells due to genetic redundancy. Here we discuss how this leads to cancer synthetic dependencies that can be exploited in therapy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.